Description: Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Home Page: www.omeros.com
OMER Technical Analysis
The Omeros Building
Seattle,
WA
98119
United States
Phone:
206 676 5000
Officers
| Name | Title |
|---|---|
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & Pres |
| Mr. Michael A. Jacobsen | Chief Accounting Officer, VP of Fin. & Treasurer |
| Mr. Peter B. Cancelmo J.D. | VP, Gen. Counsel & Corp. Sec. |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science |
| Mr. Peter W. Williams | VP of HR |
| Dr. J. Steven Whitaker J.D., M.D. | VP of Clinical Devel. & Chief Medical Officer |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems |
| Ms. Nadia Dac | VP & Chief Commercial Officer |
| Ms. Debra K. Bowes M.T | Chief Bus. Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.9143 |
| Price-to-Book MRQ: | 8.4414 |
| Price-to-Sales TTM: | 4.9338 |
| IPO Date: | 2009-10-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 213 |